<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751062</url>
  </required_header>
  <id_info>
    <org_study_id>9200PG006</org_study_id>
    <secondary_id>A6111130</secondary_id>
    <nct_id>NCT00751062</nct_id>
  </id_info>
  <brief_title>A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia</brief_title>
  <official_title>A 6-Month, Randomized, Double-Masked Comparison of PhXA41 With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-Centre Study in Scandinavia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PhXA41 is not inferior to timolol in reducing intra-ocular pressure
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 1992</start_date>
  <completion_date type="Actual">December 1993</completion_date>
  <primary_completion_date type="Actual">December 1993</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to demonstrate the IOP-reducing effect of PhXA41 is comparable to that of timolol at the end of 6 months of treatment.</measure>
    <time_frame>6 mos</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to demonstrate the IOP-reducing effect of PhXA41 administered in the morning is equivalent the effect of PhXA41 administered in the evening</measure>
    <time_frame>6 mos</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Timolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PhXA41</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>timolol</intervention_name>
    <description>One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.</description>
    <arm_group_label>Timolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PhXA41</intervention_name>
    <description>One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle</description>
    <arm_group_label>PhXA41</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary
             glaucoma or ocular hypertension.

          -  Open angle glaucoma appearing more than 6 months after cataract surgery is recognized
             as primary open angle glaucoma. (individuals requiring treatment bilaterally must
             fulfill eligibility criteria for both eyes.)

          -  IOP of 22mmHg or higher obtained during the pre-study period.

        Exclusion Criteria:

          -  History of acute angle closure.

          -  Severe trauma at any time.

          -  Intraocular surgery or argon laser trabeculoplasty within 6 months.

          -  Current use of contact lenses.

          -  History of severe dry eye syndrome.

          -  Ocular inflammation/infection with three months of inclusion.

          -  Any condition preventing reliable applanation tonometry.

          -  Unacceptable finding at pre-study ocular examination as specified in the Case Report
             Forms.

          -  In Investigator regards monotherapy insufficient with respect to optic nerve head
             and/or visual field status.

          -  Treatment of elevated IOP with any topical B-adrenergic antagonist regularly for a
             period longer than 3 months and/or treatment at any time during 6 months prior to
             study start.

          -  Cardiac failure, sinus bradycardia, second and third degree of atrio-ventricular
             block.

          -  Bronchial asthma, history of bronchial asthma or chronic obstructive pulmonary
             disease.

          -  Having participated in any other clinical study within the last month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Huddinge</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Linkoping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Malmo</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=9200PG006&amp;StudyName=A%20study%20of%20open%20angle%20glaucoma%20or%20ocular%20hypertension%20in%20patients%20within%20Scandinavia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2008</study_first_submitted>
  <study_first_submitted_qc>September 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2008</study_first_posted>
  <last_update_submitted>September 10, 2008</last_update_submitted>
  <last_update_submitted_qc>September 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>open angle glaucoma ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

